세계의 비뇨기과 치료제 시장 (2023-2030) : 질환별 (전립선, 난소, 방광, 자궁경부암, UTI 및 성병), 제품별 (호르몬 치료, 부인과), 지역별

■ 영문 제목 : Genitourinary Drugs Market Size, Share & Trends Analysis Report By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, UTI & STD), By Product (Hormonal Therapy, Gynecological), By Region, And Segment Forecasts, 2023 - 2030

Grand View Research 회사가 출판한 조사자료로, 코드는 GRV23NOV125 입니다.■ 상품코드 : GRV23NOV125
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 9월
■ 페이지수 : 110
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 의약품
■ 판매가격 / 옵션 (부가세 10% 별도)
Single User (1인 열람용)USD5,950 ⇒환산₩8,032,500견적의뢰/주문/질문
Multi User (5인 열람용)USD6,950 ⇒환산₩9,382,500견적의뢰/주문/질문
Global/corporate License (기업 열람용)USD8,950 ⇒환산₩12,082,500견적의뢰/구입/질문
가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
글로벌 비뇨기과 치료제 시장의 성장과 동향
Grand View Research사의 최신 보고서에 따르면, 세계의 비뇨기과 치료제 시장 규모는 2023년부터 2030년까지 연평균 1. 1%의 성장률로 확대되어 2030년에는 317. 5억 달러에 달할 것으로 예상됩니다. 이 분야는 주요 기업들의 고액 R&D 투자에 힘입어 신약 후보물질의 대규모 개발이 진행될 것으로 예상됩니다. 이로 인해 비뇨생식기계 질환에 대한 효율적인 치료 옵션을 제공하기 위해 비뇨생식기계 의약품 시장으로의 약물 유입이 급증할 것으로 추정됩니다.

또한, 의약품 회수 증가로 인해 표적 치료 메커니즘을 가진 비교적 새로운 첨단 의약품의 개발이 임상적으로 시급한 상황입니다. 이러한 요인들이 복합적으로 작용하여 예측 기간 동안 이 분야에 큰 성장 기회를 제공할 것으로 보입니다.

또한, 주요 시장 플레이어들의 글로벌 진출이 증가함에 따라 비뇨생식기 질환의 치료 옵션에 대한 환자와 의사의 인식 수준이 높아질 것으로 예상됩니다. 이는 예측 기간 동안 비뇨생식기 시장의 성장 잠재력을 더욱 확대할 것으로 예상됩니다. 제네릭 의약품의 경쟁 심화, 위조 의약품의 증가, 일부 특허 만료가 예상됨에 따라 시장 성장은 향후 몇 년 동안 둔화될 것으로 예상됩니다.

비뇨기과 치료제 시장 보고서 주요 내용

- 전립선암은 세계적으로 발병률이 증가함에 따라 2022년 적응증 부문에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 또한, 프로테오믹스 기술의 발전과 스크리닝 및 진단 방법의 개선이 압도적인 점유율의 배경이 된 것으로 추정됩니다.

- 2022년에는 북미가 37.0% 이상의 점유율로 세계 비뇨기과 치료제 시장을 장악할 것으로 예상됩니다. 이러한 지배적인 점유율은 이 지역에 존재하는 높은 질병 부담에 기인하며, 따라서 연구자 및 의료 전문가들이 첨단 제제 기술에 대한 경향을 촉진하고 이 분야의 성장 범위를 확대할 것으로 예상됩니다.

- 아시아 태평양 지역의 CAGR은 예측 기간 동안 4. 8%를 상회할 것으로 예상됩니다. 이러한 급격한 성장률은 의료 지출 증가, 주요 수직적 플레이어의 이니셔티브에 의한 임상 연구 및 제조 시설의 인프라 품질 향상에 기인합니다.

- 주요 업체들은 더 큰 시장 점유율을 확보하고 이 분야에서 입지를 강화하기 위해 신제품 개발 및 공동 전략을 채택하고 있습니다. 예를 들어, 노바티스 AG는 2023년 3월 아두로 바이오텍(Aduro Biotech)과의 제휴를 통해 암 면역치료 연구 이니셔티브를 더욱 강화하여 차세대 암 면역치료제 발굴 및 개발을 위한 활동을 강화하고 있습니다.
■ 보고서 개요

Chapter 1. 조사 방법 및 범위
Chapter 2. 개요
Chapter 3. 세계의 비뇨기과 치료제 시장 변수/동향/범위
Chapter 4. 세계의 비뇨기과 치료제 시장 : 질환별 예측 및 동향 분석
Chapter 5. 세계의 비뇨기과 치료제 시장 : 제품별 예측 및 동향 분석
Chapter 6. 세계의 비뇨기과 치료제 시장 : 지역별 예측 및 동향 분석
Chapter 7. 경쟁 현황

■ 보고서 목차

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Indication
1.1.2. Product
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Indication outlook
2.2.2. Product outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Genitourinary Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Genitourinary Drugs Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic Landscape
Chapter 4. Genitourinary Drugs Market: Indication Estimates & Trend Analysis
4.1. Genitourinary Drugs Market: Key Takeaways
4.2. Genitourinary Drugs Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Prostate Cancer
4.3.1. Prostate cancer market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Ovarian Cancer
4.4.1. Ovarian cancer market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Bladder Cancer
4.5.1. Bladder cancer market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Cervical Cancer
4.6.1. Cervical cancer market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Renal Cancer
4.7.1. Renal cancer market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Erectile Dysfunction
4.8.1. Erectile dysfunction market estimates and forecasts, 2018 to 2030 (USD Million)
4.9. Urinary Tract Infections
4.9.1. Urinary tract infections market estimates and forecasts, 2018 to 2030 (USD Million)
4.10. Urinary Incontinence & Overactive Bladder
4.10.1. Urinary incontinence & overactive bladder market estimates and forecasts, 2018 to 2030 (USD Million)
4.11. Sexually Transmitted Diseases
4.11.1. Sexually transmitted diseases market estimates and forecasts, 2018 to 2030 (USD Million)
4.12. Interstitial Cystitis
4.12.1. Interstitial cystitis market estimates and forecasts, 2018 to 2030 (USD Million)
4.13. Hematuria
4.13.1. Hematuria market estimates and forecasts, 2018 to 2030 (USD Million)
4.14. Benign Prostatic Hyperplasia
4.14.1. Benign prostatic hyperplasia market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Genitourinary Drugs Market: Product Estimates & Trend Analysis
5.1. Genitourinary Drugs Market: Key Takeaways
5.2. Genitourinary Drugs Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Urologicals
5.3.1. Urologicals market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Hormonal Therapy
5.4.1. Hormonal therapy market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Gynecological
5.5.1. Gynecological market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Anti-infectives
5.6.1. Anti-infectives market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Genitourinary Drugs Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Genitourinary Drugs Market by Region: Key Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Abbott
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Bristol-Myers Squibb Co.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Novartis AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Genentech, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. F. Hoffmann-La Roche Ltd.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Ionis Pharmaceuticals, Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Eli Lilly and Company
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Merck & Co. Inc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Pfizer, Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. AstraZeneca
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. GlaxoSmithKline
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Teva Pharmaceutical Industries Ltd.
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Bayer AG
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. Allergan.
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
7.2.15. Antares Pharma
7.2.15.1. Company Overview
7.2.15.2. Financial performance
7.2.15.3. Product benchmarking
7.2.15.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 North America genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 3 North America genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 4 North America genitourinary drugs market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 6 U.S. genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 7 Canada genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 8 Canada genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 9 Europe genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 10 Europe genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 11 Europe genitourinary drugs market, by region, 2018 - 2030 (USD Million)
Table 12 Germany genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 13 Germany genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 14 UK genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 15 UK genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 16 France genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 17 France genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 18 Italy genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 19 Italy genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 20 Spain genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 21 Spain genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 22 Sweden genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 23 Sweden genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 24 Norway genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 25 Norway genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 26 Denmark genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 27 Denmark genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 28 Asia Pacific genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 29 Asia Pacific genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 30 Asia Pacific genitourinary drugs market, by region, 2018 - 2030 (USD Million)
Table 31 China genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 32 China genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 33 Japan genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 34 Japan genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 35 India genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 36 India genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 37 Australia genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 38 Australia genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 39 Thailand genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 40 Thailand genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 41 South Korea genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 42 South Korea genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 43 Latin America genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 44 Latin America genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 45 Latin America genitourinary drugs market, by region, 2018 - 2030 (USD Million)
Table 46 Brazil genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 47 Brazil genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 48 Mexico genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 49 Mexico genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 50 Argentina genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 51 Argentina genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 53 Middle East and Africa genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa genitourinary drugs market, by region, 2018 - 2030 (USD Million)
Table 55 South Africa genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 56 South Africa genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 59 UAE genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 60 UAE genitourinary drugs market, by product, 2018 - 2030 (USD Million)
Table 61 Kuwait genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
Table 62 Kuwait genitourinary drugs market, by product, 2018 - 2030 (USD Million)
보고서 이미지

※본 조사보고서 [세계의 비뇨기과 치료제 시장 (2023-2030) : 질환별 (전립선, 난소, 방광, 자궁경부암, UTI 및 성병), 제품별 (호르몬 치료, 부인과), 지역별] (코드 : GRV23NOV125) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [세계의 비뇨기과 치료제 시장 (2023-2030) : 질환별 (전립선, 난소, 방광, 자궁경부암, UTI 및 성병), 제품별 (호르몬 치료, 부인과), 지역별] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!